Briviact - (10, 25, 50, 75 and 100 mg; Tablet, Oral)

Generic Name	Brivaracetam	**Innovator**	UCB pharma
Dosage	10, 25, 50, 75 and 100 mg; Tablet, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	More Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	More Than 5	**Generic Launches**	Less Than 5
Indication	Indicated for the treatment of partial-onset seizures in patients 4 years of age and older.		
Complexities	Yes		

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Briviact - (50 mg/5 ml; Solution, Intravenous)

Generic Name	Brivaracetam	**Innovator**	UCB pharma
Dosage	50 mg/5 ml; Solution, Intravenous	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	None
Indication	Briviact is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Briviact - (10 mg/ml; Solution, Oral)

Generic Name	Brivaracetam	**Innovator**	UCB pharma
Dosage	10 mg/ml; Solution, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Briviact is indicated for the treatment of partial-onset seizures in patients 4 years of age and older		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.